U.S. markets closed
  • S&P 500

    3,841.94
    +73.47 (+1.95%)
     
  • Dow 30

    31,496.30
    +572.20 (+1.85%)
     
  • Nasdaq

    12,920.15
    +196.65 (+1.55%)
     
  • Russell 2000

    2,192.21
    +45.29 (+2.11%)
     
  • Crude Oil

    66.28
    +0.19 (+0.29%)
     
  • Gold

    1,698.20
    -0.30 (-0.02%)
     
  • Silver

    25.30
    +0.01 (+0.03%)
     
  • EUR/USD

    1.1919
    -0.0060 (-0.50%)
     
  • 10-Yr Bond

    1.5540
    +0.0040 (+0.26%)
     
  • GBP/USD

    1.3817
    -0.0077 (-0.55%)
     
  • USD/JPY

    108.3440
    +0.3680 (+0.34%)
     
  • BTC-USD

    50,108.39
    +1,611.70 (+3.32%)
     
  • CMC Crypto 200

    982.93
    +39.75 (+4.21%)
     
  • FTSE 100

    6,630.52
    -20.36 (-0.31%)
     
  • Nikkei 225

    28,864.32
    -65.78 (-0.23%)
     

Concert Pharmaceuticals to Present at The JMP Securities CNS Forum

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that James V. Cassella, Ph.D., Chief Development Officer, will be participating virtually in a fireside chat at The JMP Securities CNS Forum on August 19, 2020, at 10:00 a.m. ET. A live webcast of the event may be accessed in the Investors section of the Company’s website at www.concertpharma.com.

About Concert

Concert Pharmaceuticals is a clinical stage biopharmaceutical company focused on applying its DCE Platform® (deuterated chemical entity platform) to create novel medicines designed to treat serious diseases and address unmet patient needs. The Company’s approach starts with previously studied compounds, including approved drugs, in which deuterium substitution has the potential to enhance clinical safety, tolerability or efficacy. Concert’s pipeline of innovative medicines targets autoimmune diseases and central nervous systems (CNS) disorders. For more information please visit www.concertpharma.com or follow us on Twitter at @ConcertPharma or on LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200818005174/en/

Contacts

Justine Koenigsberg
(781) 674-5284
ir@concertpharma.com